Filippo De Braud, MD
Patients with ROS1
-positive and NTRK
-positive non–small cell lung cancer (NSCLC) had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib (Rozlytrek), an integrated analysis of three clinical trials suggested.1
The analysis showed objective response rates of 79.2% for patients with ROS1
-positive NSCLC and 70% for those with NTRK
-positive NSCLC. During an additional 5 months of follow-up since prior analyses, 2 more patients with ROS1-positive disease achieved complete responses.
Median duration of response exceeded 2 years in the ROS1
-positive group, Filippo De Braud, MD, of the Istituto Nazionale dei Tumori in Milan, reported at 2019 ESMO Congress.
... to read the full story